Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

Letter Gastroenterology & Hepatology

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease

Joshua Quan et al.

GUT (2023)

Article Gastroenterology & Hepatology

Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID

Kimberly N. Weaver et al.

Summary: The severe acute respiratory syndrome coronavirus 2 vaccine is safe and well tolerated among individuals with inflammatory bowel disease (IBD) with low rates of adverse events and flare-ups.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study

Gilaad G. Kaplan et al.

GUT (2022)

Add to Collection

Review Gastroenterology & Hepatology

Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

Deepak James et al.

Summary: COVID-19 vaccination in patients with IBD appears to be safe, with only mild adverse events reported. The incidence of flares of IBD and severe adverse events requiring hospitalization was low.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Immunology

Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals

Elena Azzolini et al.

Summary: Adverse events following BNT162b2 vaccination are common and may be associated with IgG response. Female sex, younger age, receiving the second dose of the vaccine, and previous COVID-19 infection are independently associated with adverse events. Subjects with adverse events demonstrate a significantly higher IgG response, particularly those experiencing myalgia, fever, and lymphadenopathy.

VACCINES (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

Joshua Quan et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Oncology

COVID-19 vaccination associated severe immune thrombocytopenia

Syed Raza Ali Shah et al.

Summary: This study reports three cases of severe immune thrombocytopenia (ITP) following COVID-19 vaccination and their clinical course. Treatment with oral immunoglobulin and dexamethasone resulted in improvement in platelet counts for all cases, indicating a potential effective management approach for vaccine-induced ITP.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States

Yousaf Bashir Hadi et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease

Gregory J. Botwin et al.

Summary: Patients with immune-mediated inflammatory diseases like IBD who are on immunosuppressive and biologic therapies were largely excluded from COVID-19 mRNA vaccine trials. A study on 246 adults with IBD found that adverse events after mRNA vaccination were similar to the general population. Adverse events were more common in younger patients and those with previous COVID-19, but less common in individuals receiving advanced therapies with biologics or small-molecule inhibitors.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

Related references

Export Citation

Share Paper